The neuropsychopharmacology of cannabis: A review of human imaging studies
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 2×
“Larger-scale publicallyavailable data sets with many hundreds of subjects such as the Human Connectome Project (HCP; e.g. Pagliaccio, et al., 2015) and the UK Biobank (Sudlow et al., 2015) are also beginning to address the issues of small sample sizes and low experimental power.”
BackgroundPower failure: why small sample size undermines the reliability of neuroscience
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3475 · Cited by 7,641 · cited 2×
“There is an emerging awareness that many neuroscience studies may be severely under-powered in a statistical sense (Button et al., 2013; Nord et al., 2017) and neuroimaging studiesmay be particular examples, because their relatively high cost (in both money, and researcher time) make collecting large samples difficult.”
BackgroundInsensitivity to future consequences following damage to human prefrontal cortex
Bechara, A., Damasio, A. R., Damasio, H., & Anderson, S. W. (1994) · Cognition · doi:10.1016/0010-0277(94)90018-3 · Cited by 6,128 · cited 5×
“Using the Iowa Gambling Task (Bechara et al., 1994) and H2[(15)O]- PET (Bolla et al.”
MethodInfluentialfMRIPrep: A robust preprocessing pipeline for functional MRI
Esteban, O., Markiewicz, C. J., Blair, R. W., Moodie, C. A., Isik, A. I., Erramuzpe, A., Kent, J. D., Goncalves, M., DuPre, E., Snyder, M., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0235-4 · Cited by 3,905
Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates
Eklund, A., Nichols, T. E., & Knutsson, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602413113 · Cited by 3,487 · cited 1×
“Recent high-profile work has highlighted somewhat more subtle, but important, statistical issues (Eklund et al., 2016) which may also contribute to the production of false-positive results in the literature.”
BackgroundCannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 28×
“No significant change Ford et al. (2014) fMRI 15 [cannabis users]/15 [MDD]/14 [cannabis users with MDD]/17 [healthy controls] - Music Listening Paradigm (Neutral and Preferred Music) 20.2 (1.3) [cannabis users], 19.9 (1.7) [MDD + cannabis users] 6.8 (0.4) [cannabis users] 6.9 (0.4) [cannabis users + MDD] - 22.0 (6.2)…”
BackgroundInfluentialTrial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013.
Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung, J., Pickering, R. P., Ruan, W. J., Smith, S. M., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1858 · Cited by 1,086
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · cited 1×
“With its excellent safety and tolerability profile and lack of intoxicating effects, CBD has generated significant interest as a novel treatment for psychosis, (Leweke et al., 2012; McGuire et al., 2017) epilepsy”
Background
Cited by
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Self-citationFischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., Brink, W. V. D., et al. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103381 · Cited by 236
“PWUC should generally be aware that there are multiple possible risk-factors or -behaviors that determine their odds of experiencing adverse health outcomes from cannabis use, and that they should aim to avoid as many of these as possible to lower their risk for experiencing acute or chronic harm.”
BackgroundInfluentialAdolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence
Lorenzetti, V., Hoch, E., & Hall, W. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.03.012 · Cited by 166
Burggren, A. C., Shirazi, A., Ginder, N., & London, E. D. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1634086 · Cited by 144
Dellazizzo, L., Potvin, S., Giguère, S., & Dumais, A. (2022) · Addiction · doi:10.1111/add.15764 · Cited by 120
Zhou, X., Zimmermann, K., Xin, F., Zhao, W., Derckx, R. T., Sassmannshausen, A., Scheele, D., Hurlemann, R., Weber, B., Kendrick, K. M., et al. (2019) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.04.006 · Cited by 77
Lichenstein, S. D., Manco, N., Cope, L. M., Egbo, L., Garrison, K. A., Hardee, J., Hillmer, A. T., Reeder, K., Stern, E. F., Worhunsky, P., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01226-9 · Cited by 63
Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder
D’Souza, D. C., Radhakrishnan, R., Naganawa, M., Ganesh, S., Nabulsi, N., Najafzadeh, S., Ropchan, J., Ranganathan, M., Cortes-Briones, J., Huang, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00891-4 · Cited by 55
Skumlien, M., Mokrysz, C., Freeman, T. P., Wall, M. B., Bloomfield, M., Lees, R., Borissova, A., Petrilli, K., Carson, J., Coughlan, T., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01316-2 · Cited by 27
“Several previous studies have found increased fronto-parietal activation in cannabis users during cognitive tasks [56], especially in adolescent users [57].”
BackgroundSelf-citationHarper, J., Malone, S. M., Wilson, S., Hunt, R. H., Thomas, K. M., & Iacono, W. G. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.006 · Cited by 26
The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis
Wright, A., Cather, C., Gilman, J., & Evins, A. E. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.08.016 · Cited by 16
Gunasekera, B., Davies, C., Blest-Hopley, G., Veronese, M., Ramsey, N. F., Bossong, M. G., Radua, J., Bhattacharyya, S., Pretzsch, C., McAlonan, G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104801 · Cited by 10
Self-citationSubramaniam, P., Prescot, A., McGlade, E., Renshaw, P., & Yurgelun-Todd, D. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109326 · Cited by 9
Metadata
- Authors
- Bloomfield, M. A. P., Hindocha, C., Green, S. F., Wall, M. B., Lees, R., Petrilli, K., Costello, H., Ogunbiyi, M. O., Bossong, M. G., & Freeman, T. P.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 195
- Pages
- 132-161
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2897774008
- Cited by
- 230
- References
- 62
- FWCI
- 15.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.